241 related articles for article (PubMed ID: 33990570)
1. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.
Shi W; Zhang G; Ma Z; Li L; Liu M; Qin L; Yu Z; Zhao L; Liu Y; Zhang X; Qin J; Ye H; Jiang X; Zhou H; Sun H; Jiao Z
Nat Commun; 2021 May; 12(1):2812. PubMed ID: 33990570
[TBL] [Abstract][Full Text] [Related]
2. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
Saatci Ö; Borgoni S; Akbulut Ö; Durmuş S; Raza U; Eyüpoğlu E; Alkan C; Akyol A; Kütük Ö; Wiemann S; Şahin Ö
Oncogene; 2018 Apr; 37(17):2251-2269. PubMed ID: 29391599
[TBL] [Abstract][Full Text] [Related]
3. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
[TBL] [Abstract][Full Text] [Related]
4. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426
[TBL] [Abstract][Full Text] [Related]
5. miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer.
Guo J; Zhong X; Tan Q; Yang S; Liao J; Zhuge J; Hong Z; Deng Q; Zuo Q
Cell Death Dis; 2021 Jul; 12(7):696. PubMed ID: 34257270
[TBL] [Abstract][Full Text] [Related]
6. EGF-induced nuclear translocation of SHCBP1 promotes bladder cancer progression through inhibiting RACGAP1-mediated RAC1 inactivation.
Yin H; Zhang C; Wei Z; He W; Xu N; Xu Y; Li T; Ren K; Kuang Y; Zhu X; Yuan F; Yu H; Gou X
Cell Death Dis; 2022 Jan; 13(1):39. PubMed ID: 35013128
[TBL] [Abstract][Full Text] [Related]
7. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer.
Ishida M; Kagawa S; Shimoyama K; Takehara K; Noma K; Tanabe S; Shirakawa Y; Tazawa H; Kobayashi H; Fujiwara T
Mol Cancer Ther; 2016 Mar; 15(3):402-11. PubMed ID: 26832799
[TBL] [Abstract][Full Text] [Related]
9. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
[TBL] [Abstract][Full Text] [Related]
10. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
11. The Wnt3a/β-catenin/TCF7L2 signaling axis reduces the sensitivity of HER2-positive epithelial ovarian cancer to trastuzumab.
Shen G; Gao Q; Liu F; Zhang Y; Dai M; Zhao T; Cheng M; Xu T; Jin P; Yin W; Huang D; Weng H; Chen W; Ren H; Mu X; Wu X; Hu S
Biochem Biophys Res Commun; 2020 Jun; 526(3):685-691. PubMed ID: 32248976
[TBL] [Abstract][Full Text] [Related]
12. The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition.
Shi J; Li F; Yao X; Mou T; Xu Z; Han Z; Chen S; Li W; Yu J; Qi X; Liu H; Li G
Oncogene; 2018 May; 37(22):3022-3038. PubMed ID: 29535422
[TBL] [Abstract][Full Text] [Related]
13. NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in
Gambardella V; Gimeno-Valiente F; Tarazona N; Martinez-Ciarpaglini C; Roda D; Fleitas T; Tolosa P; Cejalvo JM; Huerta M; Roselló S; Castillo J; Cervantes A
Clin Cancer Res; 2019 Mar; 25(5):1639-1649. PubMed ID: 30504425
[TBL] [Abstract][Full Text] [Related]
14. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
[TBL] [Abstract][Full Text] [Related]
16. SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis.
Xu N; Wu YP; Yin HB; Chen SH; Li XD; Xue XY; Gou X
J Cancer Res Clin Oncol; 2020 Aug; 146(8):1953-1969. PubMed ID: 32447485
[TBL] [Abstract][Full Text] [Related]
17. An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy.
Darini C; Ghaddar N; Chabot C; Assaker G; Sabri S; Wang S; Krishnamoorthy J; Buchanan M; Aguilar-Mahecha A; Abdulkarim B; Deschenes J; Torres J; Ursini-Siegel J; Basik M; Koromilas AE
Nat Commun; 2019 May; 10(1):2139. PubMed ID: 31086176
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage.
Tsvetkov L; Stern DF
Cell Cycle; 2005 Jan; 4(1):166-71. PubMed ID: 15611664
[TBL] [Abstract][Full Text] [Related]
19. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
20. Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase.
Tokumaru Y; Tajirika T; Sugito N; Kuranaga Y; Shinohara H; Tsujino T; Matsuhashi N; Futamura M; Akao Y; Yoshida K
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30959742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]